CLEOPATRA: Pertuzumab + Trastuzumab + Docetaxel in HER2+ MBC — Mobile Quick Reference

Save for clinic

📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications

⚠️ Updated analysis. The primary endpoint (IRF-assessed PFS) was previously reported. This prespecified end-of-study analysis reports updated OS and safety at 99·9 months median follow-up.

🎯 Clinical Bottom Line

Adding pertuzumab to trastuzumab and docetaxel prolongs survival in first-line HER2-positive metastatic breast cancer, with a durable benefit sustained at over eight years of follow-up. This triplet remains the first-line standard of care. No new safety signals emerged with long-term follow-up.

Key Result: Overall survival — 57·1 vs 40·8 months, HR 0·69 (95% CI 0·58–0·82; p<0·0001)

8-Year OS Rate: 37% (95% CI 31–42) vs 23% (95% CI 19–28)

Safety Signal: Grade 3–4 neutropenia in 49% of pertuzumab arm; febrile neutropenia serious AE in 11%

✅ Patient Eligibility

Must Have:

• HER2-positive (IHC 3+ or FISH-positive)
• Metastatic breast cancer, first-line (no prior chemo/biologics for metastatic disease)
• ECOG PS 0–1
• LVEF ≥50%

Cannot Have:

• Prior chemotherapy or anti-HER2 therapy for metastatic disease (prior neo/adjuvant permitted if ≥12 months treatment-free interval)
• Concurrent hormonal therapy before progression

💊 Dosing Quick Guide

Experimental Regimen

Pertuzumab: 840 mg IV load → 420 mg IV q3w Trastuzumab: 8 mg/kg IV load → 6 mg/kg IV q3w Docetaxel: 75 mg/m² IV q3w (escalate to 100 mg/m² if tolerated); minimum 6 cycles Duration: Pertuzumab + trastuzumab until progression or intolerable toxicity

Control Regimen

Placebo (matched to pertuzumab) + trastuzumab + docetaxel (same doses)

Key Dose Modifications [2]

• Withhold pertuzumab and trastuzumab if LVEF drops to <40% or 40–45% with ≥10% absolute decrease from baseline
• No dose reductions for pertuzumab; dose delays permitted
• Cardiac monitoring (LVEF) required per prescribing information

Mechanism: Pertuzumab is a HER2 dimerization inhibitor — a monoclonal antibody targeting HER2 subdomain II that blocks HER2 heterodimerization, providing complementary HER2 blockade when combined with trastuzumab [2].

⚠️ Safety Snapshot

Key safety metrics:

• Treatment-related deaths: 5 (1%) vs 6 (2%)
• Discontinuations due to AE: 39 vs 24
• AEs leading to death during treatment: 8 (2%) vs 12 (3%)
• Cardiac (new CHF events since prior analysis): 1 event (pertuzumab group)

📊 Key Numbers

Median follow-up: 99·9 months (pertuzumab) / 98·7 months (placebo)

🔬 Key Comparator Context

Cross-trial comparisons are limited by differences in populations, designs, and endpoints.

🔍 Subgroups to Watch

Visceral disease: HR 0·60 (95% CI 0·50–0·73) — robust benefit in patients with visceral metastases Non-visceral disease: HR 1·08 (95% CI 0·72–1·62) — no apparent benefit; hypothesis-generating Asia: HR 0·85 (95% CI 0·63–1·16) — numerically smaller benefit; wide CI ER/PR negative: HR 0·64 (95% CI 0·50–0·81) — strong benefit in HR-negative subgroup Age ≥65: HR 0·55 (95% CI 0·35–0·85) — robust benefit in older patients Prior trastuzumab (post-hoc): HR 0·86 (95% CI 0·51–1·43) — uncertain benefit after prior trastuzumab

Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.

📋 Regulatory Status

⚠️ Verify current regulatory status before prescribing.

NCCN: Category 1 preferred first-line regimen for HER2+ recurrent/metastatic breast cancer [3]

⚡ Grey Zones

• No proven benefit in non-visceral disease subgroup (HR 1·08) — who can safely omit pertuzumab?
• Optimal first-line therapy after relapse on pertuzumab-based adjuvant therapy remains undefined
• Docetaxel was the only chemotherapy backbone tested — paclitaxel/vinorelbine equivalence unproven in phase 3
• Indefinite dual HER2 therapy duration not compared to fixed-duration approach
• 50 crossover patients may underestimate the true OS difference (conservative ITT analysis)

📖 Full Analysis

Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at Desktop versionkill-cancer.com

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.

References

1. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530. doi:10.1016/S1470-2045(19)30863-0
2. Perjeta (pertuzumab) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141–148.
5. DESTINY-Breast09 (NCT04784715). ClinicalTrials.gov. Accessed March 2026.